Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-396-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
There were no studies available in which the toxicokinetic properties of the registered substance were investigated.
The registered substance is a liquid with a molecular weight around 156, it is moderately soluble in water (1.2 g/L at 20°C) and is moderately lipophilic (log Pow = 2.91).
The available evidence suggests that the substance is bioavailable via the oral and dermal routes. Systemic absorption of this substance via inhalation route is expected but to a limited extent. The substance is expected to be mainly excreted in urine.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
In accordance with section 8.1.1 of Annex VIII of Regulation (EC) No 1907/2006 (REACH), the toxicokinetic profile of the substance (i.e. absorption, distribution, metabolism and elimination) was derived from the relevant available information in the dossier. The physico-chemical properties of the substance, the results obtained from acute, repeated-dose, and reproductive toxicity studies on the substance were used to predict its toxicokinetic behaviour.
Physico-chemical properties:
The substance is a multiconstituent substance, composed of of 2 different cis-trans isomers, having a relatively low molecular weight around 156 g/mol. The substance is a water soluble liquid (1.2 g/L) and is moderately lipophilic based on the octanol/water partition coefficient (log Kow = 2.91). The substance has low volatility according to its vapour pressure (10.4 Pa at 25°C).
Absorption:
Oral absorption
The physico-chemical properties described above suggest that the substance is absorbed in the gastro-intestinal tract by passive diffusion. Water-soluble substances will readily dissolve into the gastrointestinal fluids. Absorption of very hydrophilic substances by passive diffusion may be limited by the rate at which the substance partitions out of the gastrointestinal fluid. There are no ionisable groups in the parent substance so pH would not affect absorption.
These hypotheses are supported by oral adaptative systemic effects observed in the combined toxicity study with the reproduction/developmental toxicity screening test performed on the registered substance in rats by dietary administration.
Analysis of serum after six weeks of exposure indicated high urea and low chloride concentrations in animals receiving 15000 ppm. Bile acid was significantly lower than control in females at all dose levels and males at the intermediate and low dose. Cholesterol was higher than Control for males and females receiving 15000 ppm with an indication of a dose trend at 5000 ppm in males. Calcium was significantly higher than Control in males and females at 15000, at 5000 ppm in males only. Females receiving 15000 ppm had slight but significantly higher total protein higher at 15000 ppm neither albumin or albumin globulin ratios were significantly affected. At analysis during recovery week two none of the above changes were apparent.
At necropsy the liver and adrenal weights for males and females at 15000 ppm and males at 5000 ppm (liver only) were higher than Control. After 14 days recovery these differences were not apparent.
Findings seen in the kidneys of male animals comprised of hyaline droplets in the cortical tubules, cortical tubular basophilia and corticomedullary granular casts, all at generally minimal or slight severity. Hyaline droplet formation was seen in all treated male groups after six weeks of treatment but not following 14 days of recovery. Cortical tubular basophilia and corticomedullary granular casts were seen in males given 5000 and 15000 ppm of Dihydroterpineol multiconstituent. After cessation of treatment for 14 days in males given 15000 ppm there was a slight reduction in the incidence or severity of these findings, which may indicate partial recovery.
The observation of systemic effects indicates the oral bioavailability of the registered substance and/or its metabolites.
In light of these data, and the lack of specific information on oral absorption, the substance was assumed to be 100% bioavailable by oral route for the purposes of human health risk assessment.
Dermal absorption
Regarding dermal absorption, systemic absorption by the dermal route is expected to be moderate to high based on the log Kow and the water solubility values. The absence of effects in the toxicity studies probably indicates low toxicity rather than the absence of absorption.
In light of these data, the substance was conservatively assumed to be 100% bioavailable by dermal route for the purposes of human health risk assessment.
Respiratory absorption
The potential for inhalation toxicity was not evaluated in vivo.
The vapour pressure of the substance (VP = 10.4 Pa at 20°C) indicated a low volatility and therefore no exposure by inhalation is anticipated. Thus, at ambient temperature, no respiratory absorption is expected under normal use and handling of the substance.
However, when used as a vapour in aerosol, the substance is expected to be directly absorbed across the respiratory tract epithelium by passive diffusion.
In light of these data, and the lack of specific information on respiratory absorption, the substance was conservatively assumed to be 100% bioavailable by inhalation for the purposes of human health risk assessment.
Distribution
There is no experimental evidence to indicate distribution but the physico-chemical data suggests that wide distribution could occur. However, the log Kow value of 2.91 suggests that the substance would be unlikely to accumulate with the repeated intermittent exposure patterns normally encountered in the workplace but may accumulate if exposures are continuous. Distribution and bioaccumulation are highly dependent on the rate of biotransformation and elimination. There is, however, no evidence of cumulative effects from the repeated dose oral toxicity study.
Metabolism
In vitro chromosome aberration test showed some evidence of attenuation of cytotoxicity in the presence of S9 which might indicate biotransformation by microsomal enzymes (but less evident with Ames and HPRT tests).
Excretion
The parent substance is moderately water-soluble therefore some elimination of the unchanged form, in urine, might be possible. Biotransformation is expected, however, and elimination of metabolites would most likely occur in urine, although elimination of conjugates in bile is possible. The repeated exposre induced species and sex-specific renal toxic effects in male rats due to alpha2microglobulin accumulation which confirms renal excretion of the parent substance and/or its metabolites. The parent substance is not sufficiently volatile for any appreciable elimination via the lungs, in expired air.
The registered substance has log Kow=2.91 which is below the criterion of 4.5 for bioaccumulation; therefore, it is considered to have a low bioaccumulation potential.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.